Investor & media center

Corporate Overview

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC’s proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.

PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases.

PYC’s discovery and laboratory operations are located in Australia, and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and corporate operations.

Corporate Overview

Press Releases

Events

Upcoming Events Past Events

Upcoming Events

More events are coming soon

Past Events

PYC Quarterly Investor Call

04/15/2021 View Event

Turning RNA Research into Medicines Panel

02/17/2021 View Event

Webcast: PYC Therapeutics Limited

01/14/2021 View Event

Select Area of Interest

Annual Reports and Other ASX Filings Corporate Governance Charters Policies and Procedures

PYC Therapeutics Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 3rd Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Click here to read the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

Investor Relations and Media Contacts

Investors

Deborah Elson and Matthew DeYoung
Argot Partners
001.212.600.1902
deborah@argotpartners.com | matthew@argotpartners.com

Media

Leo Vartorella
Argot Partners
001.212.600.1902
leo@argotpartners.com

Discover more about our Pipeline

We are combining our proprietary CPP technology with world-leading expertise in PMO design to create a pipeline of highly precise, safe and effective combination drugs.

Our Pipeline

Investor & media center

Corporate Overview

Press Releases

2021

Second Drug Program Progressing Towards Human Trials

Evercore ISI GenomeRx Emerging Therapeutic Company Day

Second Drug Program – Efficacy Data in Patient Cell Models

PYC Invited to Present at ARVO 2021 Annual Meeting

Set To Announce Efficacy Results For Second Drug Program

March 2021 Quarterly Report and Cashflow

April Investor Call Presentation

Preclinical Data – Superior PPMO Delivery to the Brain

Quarterly Investor Call – 15th April 2021

PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board

Director Retirement

Participation in SVB Leerink Biopharma Private Co Connect

PYC Appoints US Biotech Veteran to its Board of Directors

Lead Investigational Drug Demonstrates Key Improvement

PYC Expands US Executive Leadership Team

Progress US Clinical Stage Company and Corporate Objectives

PYC to Participate in RNA Discussion – BIO CEO Conference

December 2020 Quarterly Report and Cashflow

ICR Conference Presentation

PYC to Present at ICR Westwicke Conference

2020

Visual Evidence of Lead Drugs Efficacy

Letter to Shareholders from the US CEO

Appointment of Chief Executive Officer in the United States

PYC to Present at the Evercore ISI Conference

Grants Awarded to Support Clinical Progression of Lead Drug

FDA Response to Orphan Drug Designation Request

Successful Institutional Entitlement Offer and Placement

PYC Equity Raising to Raise Up to $55 Million

New Drug for Substantial Unmet Need Added to Pipeline

Investor Call 15th Oct 2020 12pm AEDT 9am AWST

PYC’s Lead Drug Effective in Patient Derived Models Tested

Second Potential Blockbuster Drug Added to PYC’s Pipeline

Creation of Novel Gene Therapy Delivery Technology

Executive Re-structure Across Global Operations

Appointment of world-renowned Chief Scientific Officer

Investor Call – 8am AWST – Wednesday 12 August 2020

June 2020 Quarterly Activity Report and Cashflow

Successful Dose Response & Toxicity Studies in Lead Program

PYC Recruits High Profile Chief Medical Officer to US Ops

World Class Results – Lions Eye Institute News Release

March 2020 Quarterly Activities and Cash Flow Report

Efficacy and Toxicity Studies Presentation

Successful Toxicity Results Confirm Safety Advantage

Investor Call 9.00am AWST Wed 1 April 2020

NHMRC Grand for Identifying new Antisense Drugs

CEO Appointment & Establishment of US Office

Investor Call 27 February 2020

Expansion of Drug Development Pipeline

Quarterly Shareholder Update

2019

Drug Delivery Greater than 100% more Effective – Amended

Change in Substantial Holding

Drug Delivery Greater than 100%

Conclusion of Genentech Antimicrobial Collaboration

PYC Increases Shareholding in Vision Pharma

$26.8M Fully Underwritten accelerated Entitlement Offer

Drug Delivery Greater than 100%

Presentation Oligonucleotide Therapeutics Society Meeting

Succesfful Major Milestone – Human Retina in a Dish Model

Strategic Partnership and Lead Program

Successful Time-Course Studies in Animals

Scientific Advisory Board Appointment

Successful Competitive Drug Evaluation in Animals

Investor Call

Successful Time – Course Studies in Animals

Company Re-branding

Phylogica’s Technology is Effective in Human Cells

Operational Update and Appendix 4c

Animal Models – 400% Outperformance of Gold Standard

Break Through Animal Model Results

March 2019 Quarterly Operational Update

Scientific Advisory Board Appointment

Subscribe to our mailing list:

Events

Upcoming Events